Home / Health / Pill Replaces Diabetes Injections?
Pill Replaces Diabetes Injections?
9 Jun
Summary
- An experimental oral GLP-1 drug, elecoglipron, shows promise in trials.
- The drug significantly lowered blood sugar and aided weight loss.
- It offers a potential alternative to injectable diabetes medications.
An experimental oral GLP-1 drug, elecoglipron, is showing encouraging results in clinical trials, offering a potential needle-free future for millions with Type 2 diabetes and obesity. The drug, which mimics gut hormones to regulate blood sugar and reduce hunger, demonstrated significant reductions in HbA1c levels and meaningful weight loss in participants.
Presented at the American Diabetes Association's Scientific Sessions, the SOLSTICE trial involved 406 participants across nine countries. The findings indicate that a once-daily pill could overcome adherence challenges associated with current injectable GLP-1 therapies, and even oral semaglutide which has strict dosing rules.
Beyond diabetes, a separate VISTA trial showed elecoglipron led to dose-dependent weight loss in adults with obesity. Safety appears consistent with existing GLP-1s, though gastrointestinal side effects were common. Larger Phase 3 studies are necessary to confirm its efficacy and safety.
For India, where over 100 million people live with diabetes, oral GLP-1s could be particularly impactful. They may circumvent issues like needle phobia and cold-chain storage, improving access and compliance in a country with a high prevalence of diabetes among its population.
